EHA Unplugged

How Experts Treat Mantle Cell Lymphoma (with Prof Mats Jerkeman)

Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden).  In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including  the expanding role of  BTK inhibitors (such as ibrutinib) in first-line regimens. He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy  have largely supplanted but not fully replaced allogeneic transplantation. Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges.   Link to the guideline: (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) Link to Lund University:  Mats Jerkeman - Lund University Home | Lund University  Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠.What did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

Life After CAR T-cell Therapy: Jonathan Clark’s Journey with Mantle Cell Lymphoma and the Future of Patient Advocacy

[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission. Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.  Host: Dr Sarah de VliegerGuest: Jonathan ClarkThis episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠.What did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

The Role of Artificial Intelligence in Hematology (featuring Dr Gregor Hormann)

[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.   Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.  The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't." Host: Dr Wilson LimGuest: Dr Gregor HormannLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

How Does Climate Change Affect Hematology Practice? (with Dr Stephen Hibbs)

[This is a Rerelease. Episode first published on November 1, 2024.]Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.   Host: Dr Sarah de VliegerGuest: Dr Stephen HibbsLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠Provide Feedback⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠ 

Accelerating Clinical Trials with AI (with Dr Jan Moritz Middeke)

[This is a Rerelease. Episode first published on April 11, 2025.]Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design. Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies. If you want to know more: ⁠https://www.nature.com/articles/s41746-024-01076-x⁠ Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Jan Moritz MiddekeLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠https://ehaedu.org/Campus⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠Facebook: ⁠https://e-h-a.link/facebook⁠LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠